The Big Ones
SpaceX has been one of the most fervent fundraisers among private companies in recent years and it shows no signs of stopping. A securities filing indicates the spacecraft manufacturer and launch services provider has secured $1.9bn from undisclosed investors, with recent media reports putting the valuation of the round at $46bn. Its earlier backers include Google, which invested $900m at a $12bn valuation five years ago, and that valuation looks set to keep on rising for now.
Consumer electronics manufacturer Konka Group has teamed up with the Chinese city of Yancheng to put together an industry fund that will begin investing from a base of about $435m. The fund will be sized at up to $1.45bn and Konka is providing 40% of the capital. Its areas of interest include AI, semiconductors, the internet-of-things, new machinery and advanced materials.
Airbnb has announced it has confidentially filed for its long-awaited initial public offering. People were talking about an Airbnb flotation before the last downturn in the IPO markets in 2018. The rebound last year wasn’t enough to tempt it, but now, while they’re rallying for tech stocks, seems to be the right time despite a coronavirus-related hit to Airbnb’s business that saw it lay off 25% of its staff in May. The CapitalG-backed company had been valued at $26bn, down from $31bn, when it raised $1bn in debt and equity the previous month.
We have finally hit that summer lull on GUV, but there were still a few big stories. Most notably, Mission Bio, a US-based DNA analysis technology spinout of University of California, San Francisco (UCSF), has raised $70m in a series C round led by pharmaceutical firm Novo’s Novo Growth unit. Agilent Ventures, the corporate venturing arm of laboratory equipment and diagnostics services provider Agilent Technologies, also took part in the round, as did Cota Capital, Mayfield Fund and Soleus Capital. The round took the company’s total funding to more than $120m, it said, and Robert Ghenchev, head of Novo Growth, has joined its board of directors. Founded in 2014, Mission Bio has created a system called Tapestri which enables researchers and medical professionals to analyse single-cell RNA sequencing data to help develop precision medicines. The spinout leverages genomics technology from UCSF’s Abate Lab.
E-commerce group JD.com”s pharmaceutical product and medical services spinoff JD Health raised $1bn at a $6.9bn valuation last year, and now it’s agreed to add series B funding from investment manager Hillhouse Capital. The deal is set to be finalised next month and JD Health expects to get upwards of $830m from Hillhouse, an investor in its parent company since its 2012 series C round.
Last week we talked about reports that Chinese online medical insurance and crowdfunding service Waterdrop had raised $200m at a $2bn valuation, but a subsequent announcement places the size of the round at $230m. Tencent and Swiss Re co-led the round, which sources told Reuters valued Waterdrop just short of $2bn. Swiss Re has been relatively quiet in the corporate venturing space in recent years but reportedly put up $100m of the capital in this round.
Online share trading has made a big jump as the stock markets rally, and RobinHood is getting a lot of business in the US market. It has accordingly increased its valuation from $8.3bn to $11.2bn in the space of just four weeks, its latest move being to raise $200m in series G financing from investment firm D1 Capital Partners. It has now secured a total of $1.7bn and its earlier investors include Roc Nation’s Arrive subsidiary as well as Alphabet units GV and CapitalG.
Palfish is one of several Chinese online education providers to have experienced growth during Covid-19 lockdowns, and it has raised $120m in a series C round that included quantitative trading firm Susquehanna International Group. The company specialises in English tutoring and claims to have some 40 million users. It will put the funding towards improving its big data technology.
BlockFi has been one of the more frequent fundraisers in the startup space having closed five rounds in just over two years as it expands its range of digital currency services. The latest is a $50m series C round that included subsidiaries of CM Group and Siam Commercial Bank. The company has now secured more than $160m and its earlier backers include Consensys, SIG, Recruit and SoFi.
There are several VC-backed companies operating under the moniker of Element but the latest to raise money is the Germany-based bespoke insurance software provider, which has added funding from investors including Sony Financial Ventures and SBI Investment to a series A round that now stands at $46.5m. The earlier tranches featured Signal Iduna and Mitsui Sumitomo Insurance.
MDI Ventures, the corporate venturing arm of Indonesian state-owned telecommunications firm Telkom, has closed a $500m fund entirely financed by the company. It will invest between $5m and $30m in domestic digital technology developers that will get access to a range of government-owned corporations, which in turn will be able to leverage the technology required to form a digital ecosystem in the country.
Russian conglomerate Sistema may not be the most active participant in the corporate venturing space but it does have one of the largest ranges of investment, having closed a series of funds focusing on different regions and sectors. Its Sistema Asia Capital subsidiary closed a $120m India fund in 2015 and is in the midst of raising the same amount for a vehicle concentrating on Southeast Asia. Areas of interest include cybersecurity, computer vision, smart cities, urban mobility and the internet-of-things.
Pharmaceutical companies Juno Therapeutics (itself a spinout of Fred Hutchinson Cancer Research Centre, Seattle Children’s Research Institute and Memorial Sloan-Kettering Cancer Centre) and WuXi AppTec founded cancer immunotherapy developer JW Therapeutics in 2016 and now it has filed for an initial public offering in Hong Kong. Recent reports suggested JW would target $250m to $300m in the IPO having already raised more than $200m in venture funding. Juno retains a 26% stake in the company while WuXi AppTec owns about 14% of its shares.
Biologic drug developer Inhibrx has gone public, raising $119m having floated at the midpoint of its range. Inhibrx had received some $135m in equity and debt financing from investors including Eli Lilly and WuXi Biologics, and its share price followed recent trends by rising post-IPO. It’s been a bumper time for newly public companies of late, the question is how much of a bubble this represents and whether latecomers to the party could end up missing out.
Nano-X Imaging is working on a medical imaging system intended to function as a more affordable alternative to X-ray machines, and the Israeli company has set terms for an initial public offering in the US that will raise almost $106m if it floats at the top of its range. A big impetus is that existing investors including corporates Foxconn, SK Telecom and iA Financial have expressed interest in buying up to $80m of shares in the offering, which is a more than decent vote of confidence.